Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers.
Manuel Caitano Maia, Meghan Salgia, Sumanta K Pal
https://pubmed.ncbi.nlm.nih.gov/32203306/Actively Recruiting
Led by St Vincent's Hospital, Sydney · Updated on 2026-04-23
30
Participants Needed
1
Research Sites
65 weeks
Total Duration
Researchers are evaluating the effectiveness of bipolar androgen therapy BAT combined with carboplatin in men who have metastatic castrate-resistant prostate cancer mCRPC. This condition progresses despite low testosterone levels, and while androgen deprivation therapy ADT is standard, resistance develops over time. The study explores whether cycling testosterone levels can improve responses, particularly in men with DNA repair defects. Participants receive high dose testosterone enanthate injections of 500mg intramuscularly every 4 weeks alongside continuous LHRH therapy or after surgical removal of the testes, plus carboplatin chemotherapy dosed at AUC 5. This combination is being studied in a phase 2 trial to assess how well it works and its safety. During the study, mens prostate-specific antigen PSA levels will be monitored over one year to evaluate treatment response. Imaging and safety assessments will also occur to track disease progression and side effects. Participants must comply with scheduled visits, lab tests, and biopsies as part of the study, which is sponsored by St Vincents Hospital in Sydney.
CONDITIONS
Bipolar Androgen Therapy + Carboplatin in mCRPC
R
Robert Kent
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
St Vincent's Hospital, Sydney
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 year
Participants receive high dose testosterone injections every 4 weeks in combination with ongoing LHRH therapy or post-orchidectomy plus Carboplatin chemotherapy as per standard procedures.
Monthly visits for injections and assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Manuel Caitano Maia, Meghan Salgia, Sumanta K Pal
https://pubmed.ncbi.nlm.nih.gov/32203306/Benjamin A Teply, Hao Wang, Brandon Luber...
https://pubmed.ncbi.nlm.nih.gov/29248236/Michael T Schweizer, Hao Wang, Brandon Luber...
https://pubmed.ncbi.nlm.nih.gov/27338150/St Vincent's Hospital, Sydney
Lead Sponsor